Interleukin-7 and interleukin-15 for cancer

Paul Zarogoulidis; Sofia Lampaki; Lonny Yarmus; Ioannis Kioumis; Georgia Pitsiou; Nikolaos Katsikogiannis; Wolfgang Hohenforst-Schmidt; Qiang Li; Haidong Huang; Antonios Sakkas; John Organtzis; Leonidas Sakkas; Ioannis Mpoukovinas; Kosmas Tsakiridis; George Lazaridis; Konstantinos Syrigos; Konstantinos Zarogoulidis

doi:10.7150/jca.10471

Interleukin-7 and interleukin-15 for cancer

Paul Zarogoulidis, Sofia Lampaki, Lonny Yarmus, Ioannis Kioumis, Georgia Pitsiou, Nikolaos Katsikogiannis, Wolfgang Hohenforst-Schmidt, Qiang Li, Haidong Huang, Antonios Sakkas, John Organtzis, Leonidas Sakkas, Ioannis Mpoukovinas, Kosmas Tsakiridis, George Lazaridis, Konstantinos Syrigos, Konstantinos Zarogoulidis

School of Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

Interleukin 7 and 15 are considered powerful pro-inflammatory cytokines, they have the ability to destabilize chromosomes and induce tumorigenesis. Additionally, they can control malignancy proliferation by influencing the tumor microenvironment and immune system. Immunotherapy has been proposed as a treatment modality for malignancy for over a decade; the exact mechanisms of action and pathways are still under investigation. Interleukin 7 and 15 have been extensively investigated in hematological malignancies since their mode of action influences the stimulation of the immune system in a more direct way than other malignancies such as lung, melanoma, and breast, renal and colorectal cancer.

Original language	English (US)
Pages (from-to)	765-773
Number of pages	9
Journal	Journal of Cancer
Volume	5
Issue number	9
DOIs	https://doi.org/10.7150/jca.10471
State	Published - 2014

Keywords

Cancer
IL-15
IL-7
Imunomodulation

ASJC Scopus subject areas

Oncology

Access to Document

10.7150/jca.10471

Cite this

Zarogoulidis, P., Lampaki, S., Yarmus, L., Kioumis, I., Pitsiou, G., Katsikogiannis, N., Hohenforst-Schmidt, W., Li, Q., Huang, H., Sakkas, A., Organtzis, J., Sakkas, L., Mpoukovinas, I., Tsakiridis, K., Lazaridis, G., Syrigos, K., & Zarogoulidis, K. (2014). Interleukin-7 and interleukin-15 for cancer. Journal of Cancer, 5(9), 765-773. https://doi.org/10.7150/jca.10471

Interleukin-7 and interleukin-15 for cancer. / Zarogoulidis, Paul; Lampaki, Sofia; Yarmus, Lonny; Kioumis, Ioannis; Pitsiou, Georgia; Katsikogiannis, Nikolaos; Hohenforst-Schmidt, Wolfgang; Li, Qiang; Huang, Haidong; Sakkas, Antonios; Organtzis, John; Sakkas, Leonidas; Mpoukovinas, Ioannis; Tsakiridis, Kosmas; Lazaridis, George; Syrigos, Konstantinos; Zarogoulidis, Konstantinos.

In: Journal of Cancer, Vol. 5, No. 9, 2014, p. 765-773.

Research output: Contribution to journal › Review article › peer-review

Zarogoulidis, Paul ; Lampaki, Sofia ; Yarmus, Lonny ; Kioumis, Ioannis ; Pitsiou, Georgia ; Katsikogiannis, Nikolaos ; Hohenforst-Schmidt, Wolfgang ; Li, Qiang ; Huang, Haidong ; Sakkas, Antonios ; Organtzis, John ; Sakkas, Leonidas ; Mpoukovinas, Ioannis ; Tsakiridis, Kosmas ; Lazaridis, George ; Syrigos, Konstantinos ; Zarogoulidis, Konstantinos. / Interleukin-7 and interleukin-15 for cancer. In: Journal of Cancer. 2014 ; Vol. 5, No. 9. pp. 765-773.

@article{1c56b5c53f994d9eb1a32f54ccbc83b4,

title = "Interleukin-7 and interleukin-15 for cancer",

abstract = "Interleukin 7 and 15 are considered powerful pro-inflammatory cytokines, they have the ability to destabilize chromosomes and induce tumorigenesis. Additionally, they can control malignancy proliferation by influencing the tumor microenvironment and immune system. Immunotherapy has been proposed as a treatment modality for malignancy for over a decade; the exact mechanisms of action and pathways are still under investigation. Interleukin 7 and 15 have been extensively investigated in hematological malignancies since their mode of action influences the stimulation of the immune system in a more direct way than other malignancies such as lung, melanoma, and breast, renal and colorectal cancer.",

keywords = "Cancer, IL-15, IL-7, Imunomodulation",

author = "Paul Zarogoulidis and Sofia Lampaki and Lonny Yarmus and Ioannis Kioumis and Georgia Pitsiou and Nikolaos Katsikogiannis and Wolfgang Hohenforst-Schmidt and Qiang Li and Haidong Huang and Antonios Sakkas and John Organtzis and Leonidas Sakkas and Ioannis Mpoukovinas and Kosmas Tsakiridis and George Lazaridis and Konstantinos Syrigos and Konstantinos Zarogoulidis",

note = "Publisher Copyright: {\textcopyright} Ivyspring International Publisher.",

year = "2014",

doi = "10.7150/jca.10471",

language = "English (US)",

volume = "5",

pages = "765--773",

journal = "Journal of Cancer",

issn = "1837-9664",

publisher = "Ivyspring International Publisher",

number = "9",

}

TY - JOUR

T1 - Interleukin-7 and interleukin-15 for cancer

AU - Zarogoulidis, Paul

AU - Lampaki, Sofia

AU - Yarmus, Lonny

AU - Kioumis, Ioannis

AU - Pitsiou, Georgia

AU - Katsikogiannis, Nikolaos

AU - Hohenforst-Schmidt, Wolfgang

AU - Li, Qiang

AU - Huang, Haidong

AU - Sakkas, Antonios

AU - Organtzis, John

AU - Sakkas, Leonidas

AU - Mpoukovinas, Ioannis

AU - Tsakiridis, Kosmas

AU - Lazaridis, George

AU - Syrigos, Konstantinos

AU - Zarogoulidis, Konstantinos

PY - 2014

Y1 - 2014

N2 - Interleukin 7 and 15 are considered powerful pro-inflammatory cytokines, they have the ability to destabilize chromosomes and induce tumorigenesis. Additionally, they can control malignancy proliferation by influencing the tumor microenvironment and immune system. Immunotherapy has been proposed as a treatment modality for malignancy for over a decade; the exact mechanisms of action and pathways are still under investigation. Interleukin 7 and 15 have been extensively investigated in hematological malignancies since their mode of action influences the stimulation of the immune system in a more direct way than other malignancies such as lung, melanoma, and breast, renal and colorectal cancer.

AB - Interleukin 7 and 15 are considered powerful pro-inflammatory cytokines, they have the ability to destabilize chromosomes and induce tumorigenesis. Additionally, they can control malignancy proliferation by influencing the tumor microenvironment and immune system. Immunotherapy has been proposed as a treatment modality for malignancy for over a decade; the exact mechanisms of action and pathways are still under investigation. Interleukin 7 and 15 have been extensively investigated in hematological malignancies since their mode of action influences the stimulation of the immune system in a more direct way than other malignancies such as lung, melanoma, and breast, renal and colorectal cancer.

KW - Cancer

KW - IL-15

KW - IL-7

KW - Imunomodulation

UR - http://www.scopus.com/inward/record.url?scp=84920935242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920935242&partnerID=8YFLogxK

U2 - 10.7150/jca.10471

DO - 10.7150/jca.10471

M3 - Review article

C2 - 25368677

AN - SCOPUS:84920935242

VL - 5

SP - 765

EP - 773

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 9

ER -

Interleukin-7 and interleukin-15 for cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this